Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
GUSTO (STH20772) is a study for bladder cancer patients. Patients will be randomised to receive either standard care or the intervention treatment, which is selected following gene expression subtyping. Some of the patients on the intervention arm will receive the two drugs Durvalumab & Tremelimumab. Durvalumab & Tremelimumab are being provided free of charge by AstraZeneca, however, they will need to be stored and distritubed to 20 UK sites (including STH) over a 4 year period. The aim of the study is to obtain information to understand whether this approach could improve outcomes and to guide the design of a larger subsequent trial.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| ROYAL FREE LONDON NHS FOUNDATION TRUST (PHARMACY) | - | £73,258 | - |